A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Trial Profile

A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

At a glance

  • Drugs OPB 111077 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 07 May 2017 Planned End Date changed from 1 Sep 2016 to 1 Nov 2017.
    • 07 May 2017 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2017.
    • 27 Jan 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top